Intrathecal Analgesia

Anesthesiology Clinics

Volumn 25, Issue 4, 2007, Pages 863-882

  Cohen, Steven P ^a,b   Dragovich, Anthony ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BACLOFEN; BUPIVACAINE; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; FENTANYL; HYDROMORPHONE; KETAMINE; MIDAZOLAM; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OMEGA CONOTOXIN MVIIA; OPIATE; OPIATE AGONIST; OPIATE RECEPTOR; PETHIDINE; SUFENTANIL;

AMENORRHEA; ANALGESIA; APPETITE DISORDER; ASTHMA; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONVULSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; HUMAN; HYPOTHYROIDISM; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; LOW BACK PAIN; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SWEATING; TREATMENT RESPONSE; URINE RETENTION; VOMITING; XEROSTOMIA;

ANALGESIA; ANALGESIA, EPIDURAL; ANALGESICS; ANESTHESIA, SPINAL; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; PAIN;

EID: 36549048908     PISSN: 19322275     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anclin.2007.07.001     Document Type: Review

References (96)

1. Pert C.B., and Snyder S. Opiate receptor: demonstration in nervous tissue. Science 179 77 (1973) 1011-1014
2. Terenius L. Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fractions from rat brain. Acta Pharmacol Toxicol (Copenh) 33 5 (1973) 377-384
3. Yaksh T.L., and Rudy T.A. Studies on the direct spinal action of narcotics in the production of analgesia in the rat. J Pharmacol Exp Ther 202 2 (1977) 411-428
4. Wang J.K., Nauss L.A., and Thomas J.E. Pain relief by intrathecally applied morphine in man. Anesthesiology 50 2 (1979) 149-151
5. Foley K.M. Treatment of cancer pain. N Engl J Med 313 2 (1985) 84-95
6. Krames E.S. Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage 8 1 (1993) 36-46
7. Kalso E., Edwards J.E., Moore R.A., et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112 3 (2004) 372-380
8. Ives T.J., Chelminski P.R., Hammett-Stabler C.A., et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 6 (2006) 46
9. Ballantyne J.C., and Mao J. Opioid therapy for chronic pain. N Engl J Med 349 20 (2003) 1943-1953
10. Webster L.R., and Webster R.M. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 6 6 (2006) 432-442
11. Kittelberger K.P., Buchheit T.E., and Rice S.F. Self-extraction of intrathecal pump opioid. Anesthesiology 101 3 (2004) 807
12. Staats P.S., Yearwood T., Charapata S.G., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291 1 (2004) 63-70
13. Akil H., Watson S.J., Young E., et al. Endogenous opioids: biology and function. Annu Rev Neurosci 7 (1984) 223-255
14. Reisine T. Opiate receptors. Neuropharmacology 34 5 (1995) 463-472
15. Ocana M., Cendan C.M., Cobos E.J., et al. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 500 1-3 (2004) 203-219
16. Smith T.J., Staats P.S., Deer T., et al. Implantable Drug Delivery Systems Study Group. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain. Impact on pain, drug-related toxicity, and survival. J Clin Oncol 20 19 (2002) 4040-4049
17. Rauck R.L., Cherry D., Boyer M.F., et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 4 8 (2003) 441-447
18. Zeppetella G., O'Doherty C.A., and Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med 15 3 (2001) 243-246
19. Portenoy R.K., and Hagen N.A. Breakthrough pain: definition, prevalence and characteristics. Pain 41 3 (1990) 273-281
20. Idanpaan-Heikkila J.J., and Guilbaud G. Pharmacological studies on a rat model of trigeminal neuropathic pain: baclofen, but not carbamazepine, morphine or tricyclic antidepressants, attenuates the allodynia-like behavior. Pain 79 2-3 (1999) 281-290
21. Hanks G.W., and Forbes K. Opioid responsiveness. Acta Anaesthesiol Scand 41 1 Pt 2 (1997) 154-158
22. Thimineur M.A., Kravitz E., and Vodapally M.S. Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. Pain 109 3 (2004) 242-249
23. Plummer J.L., Cherry D.A., Cousins M.J., et al. Long-term spinal administration of morphine in cancer and non-cancer pain: a retrospective study. Pain 44 3 (1991) 215-220
24. Krames E.S., and Lanning R.M. Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage 8 8 (1993) 539-548
25. Kanoff R.B. Intraspinal delivery of opiates by an implantable, programmable pump in patients with chronic, intractable pain of nonmalignant origin. J Am Osteopath Assoc 94 6 (1994) 487-493
26. Hassenbusch S.J., Stanton-Hicks M., Covington E.C., et al. Long-term intraspinal infusions of opiods in the treatment of neuropathic pain. J Pain Symptom Manage 10 7 (1995) 527-543
27. Winkelmuller M., and Winkelmuller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 85 3 (1996) 458-467
28. Paice J.A., Penn R.D., and Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 11 2 (1996) 71-80
29. Yoshida G.M., Nelson R.W., and Capen D.A. Evaluation of contiuous intraspinal narcotic analgesia for chronic pain from benign causes. Am J Orthop 25 10 (1996) 693-694
30. Tutak U., and Doleys D.M. Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. South Med J 89 3 (1996) 295-300
31. Angel I.F., Gould Jr. H.J., and Carey M.E. Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. Surg Neurol 49 1 (1998) 92-99
32. Anderson V.C., and Burchiel K.J. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 44 2 (1999) 289-300
33. Willis K.D., and Doleys D.M. The effects of long-term intraspinal infusion therapy with noncancer pain patients: evaluation of patient, significant-other, and clinic staff appraisals. Neuromodulation 2 4 (1999) 241-253
34. Kumar K., Kelly M., and Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol 55 (2001) 79-88
35. Roberts L.J., Finch P.M., Goucke C.R., et al. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain 5 4 (2001) 353-361
36. Anderson V.C., Cooke B., and Burchiel K.J. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med 2 4 (2001) 287-297
37. Deer T., Chapple I., Classen A., et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for low back pain. Pain Med 5 1 (2004) 6-13
38. Cherry D.A., Gourlay G.K., and Eldredge K.A. Management of chronic intractable angina: spinal opioids offer an alternative therapy. Pain 102 1-2 (2003) 163-166
39. Njee T.B., Irthum B., Roussel P., et al. Intrathecal morphine infusion for chronic non-malignant pain: a multiple center retrospective study. Neuromodulation 7 4 (2004) 249-259
40. Du Pen S., Du Pen A., and Hillyer J. Intrathecal hydromorphone for intractable nonmalignant pain: a retrospective study. Pain Med 7 1 (2006) 10-15
41. Yaksh T.L., Hassenbusch S., Burchiel K., et al. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med 3 4 (2002) 300-312
42. Paice J.A., Penn R.D., and Ryan W. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symtom Manage 9 2 (1994) 126-131
43. Aldrete J.A., and Couto da Silva J.M. Leg edema from intrathecal opiate infusions. Eur J Pain 4 4 (2000) 361-365
44. Sjoberg M., Nitescu P., Appelgren L., et al. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology 80 2 (1994) 284-297
45. Sjoberg M., Appelgren L., Einarsson S., et al. Long-term intrathecal morphine and bupivacaine in "refractory" cancer pain. I. Results from the first series of 52 patients. Acta Anaesthesiol Scand 35 1 (1991) 30-43
46. van Dongen R.T., Crul B.J., and De Bock M. Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain 55 1 (1993) 119-123
47. van Dongen R.T., Crul B.J., and van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 15 3 (1999) 166-172
48. Deer T.R., Caraway D.L., Kim C.K., et al. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J 2 4 (2002) 274-278
49. Rainov N.G., Heidecke V., and Burkert W. Long-term intrathecal infusion of drug combinations for chronic back and leg pain. J Pain Symptom Manage 22 4 (2001) 862-871
50. Berde C.B., Sethna N.F., and Conrad L.S. Subarachnoid bupivacaine analgesia for seven months for a patient with a spinal cord tumor. Anesthesiology 72 6 (1990) 1094-1096
51. Vanegas H., and Schaible H. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 85 1-2 (2000) 9-18
52. McGivern J.G. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today 11 5-6 (2006) 245-253
53. Rauck R.L., Wallace M.S., Leong M.S., et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 31 5 (2006) 393-406
54. Thompson J.C., Dunbar E., and Laye R.R. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician 9 2 (2006) 147-152
55. Hassenbusch S.J., Portenoy R.K., Cousins M., et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage 27 6 (2004) 540-563
56. Kamibayashi T., and Maze M. Clinical uses of alpha 2-adrenergic agonists. Anesthesiology 93 5 (2000) 1345-1349
57. Walker S.M., Goudas L.C., Cousins M.J., et al. Combination spinal analgesic chemotherapy: a systematic review. Anesth Analg 95 3 (2002) 674-715
58. Siddall P.J., Molloy A.R., Walker S., et al. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg 91 6 (2000) 1493-1498
59. Uhle E.I., Becker R., Gatscher S., et al. Continuous intrathecal clonidine administration for the treatment of neuropathic pain. Stereotact Funct Neurosurg 75 4 (2000) 167-175
60. Eisenach J.C., De Kock M., and Klimscha W. Alpha (2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology 85 3 (1996) 655-674
61. Middleton J.W., Siddall P.J., and Walker S. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil 77 8 (1996) 824-826
62. Raphael J.H., Southall J.L., Gnanadurai T.V., et al. Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain. BMC Musculoskelet Disord 3 (2002) 17
63. Ackerman L.L., Follett K.A., and Rosenquist R.W. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 26 1 (2003) 668-677
64. Cohen S.P., Chang A.S., Larkin T., et al. The IV ketamine test: a predictive response tool for an oral dextromethorphan treatment regimen in neuropathic pain. Anesth Analg 99 6 (2004) 1753-1759
65. Bion J.F. Intrathecal ketamine for war surgery. A preliminary study under field conditions. Anaesthesia 39 10 (1984) 1023-1028
66. Hawksworth C., and Serpell M. Intrathecal anesthesia with ketamine. Reg Anesth Pain Med 23 3 (1998) 283-288
67. Kathirvel S., Sadhasivam S., Saxena A., et al. Effects of intrathecal ketamine added to bupivacaine for spinal anaesthesia. Anaesthesia 55 9 (2000) 899-904
68. Togal T., Demirbilek S., Koroglu A., et al. Effects of S(+) ketamine added to bupivacaine for spinal anaesthesa for prostate surgery in elderly patients. Eur J Anaesthesiol 21 3 (2004) 193-197
69. Benrath J., Scharbert G., Gustorff B., et al. Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain. Br J Anaesth 95 2 (2005) 247-249
70. Muller A., and Lemos D. Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture. Ann Fr Anesth Reanim 15 3 (1996) 271-276
71. Vranken J.H., van der Vegt M.H., Kal J.E., et al. Treatment of neuropathic cancer pain with continuous intrathecal administration of S + -ketamine. Acta Anaesthesiol Scand 48 2 (2004) 249-252
72. Yang C.Y., Wong C.S., Chang J.Y., et al. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 43 4 (1996) 379-383
73. Karpinski N., Dunn J., Hansen L., et al. Subpial vacuolar myelopathy after intrathecal ketamine: report of a case. Pain 73 1 (1997) 103-105
74. Stotz M., Oehen H.P., and Gerber H. Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report. J Pain Symptom Manage 18 3 (1999) 223-228
75. Vranken J.H., Troost D., Wegener J.T., et al. Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. Pain 117 1-2 (2005) 231-235
76. B receptor pharmacology. Annu Rev Pharmacol Toxicol 33 (1993) 109-147
77. Yaksh T.L., and Allen J.W. The use of intrathecal midazolam in humans: A case study of process. Anesth Analg 98 6 (2004) 1536-1545
78. Serrao J.M., Marks R.L., Morley S.J., et al. Intrathecal midazolam for the treatment of chronic mechanical low back pain; a controlled comparison with epidural steroid in a pilot study. Pain 48 1 (1992) 5-12
79. Borg P.A., and Krijnen J.H. Long-term intrathecal administration of midazolam and clonidine. Clin J Pain 12 1 (1996) 63-68
80. Yanez A., Peleteiro R., and Camba M.A. [Intrathecal administration of morphine, midazolam, and their combination in 4 patients with chronic pain]. Rev Esp Anestesiol Reanim 39 1 (1992) 40-42 [in Spanish]
81. Ugur B., Basaloglu K., Yurtseven T., et al. Neurotoxicity with single dose intrathecal midazolam administration. Eur J Anaesthesiol 22 12 (2005) 907-912
82. Bahar M., Cohen M.L., Grinshpon Y., et al. Spinal anaesthesia with midazolam in the rat. Can J Anaesth 44 2 (1997) 208-215
83. Johansen M.J., Gradert T.L., and Satterfield W.C. Safety of continuous intrathecal midazolam infusion in the sheep model. Anesth Analg 98 6 (2004) 1528-1535
84. Tucker A.P., Lai C., Nadeson R., et al. Intrathecal midazolam. I. A cohort study investigating safety. Anesth Analg 98 6 (2004) 1512-1520
85. Hwang J.H., and Yaksh T.L. The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. Pain 70 1 (1997) 15-22
86. Slonimski M., Abram S., and Zuniga R. Intrathecal baclofen in pain management. Reg Anesth Pain Med 29 3 (2004) 269-276
87. Taricco M., Adone R., Pagliacci C., et al. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2 (2000) CD00131
88. Beard S., Hunn A., and Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 7 40 (2003) 1-111
89. van Hilten B.J., van de Beek W.T., Hoff J.I., et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 343 9 (2000) 625-630
90. Zuniga R.E., Perera S., and Abram S.E. Intrathecal baclofen: a useful agent in the treatment of well-established complex regional pain syndrome. Reg Anesth Pain Med 27 1 (2002) 90-93
91. Herman R.M., D'Luzansky J.C., and Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions. Clin J Pain 8 4 (1992) 338-345
92. Taira T., Kawamura H., Tanikawa T., et al. A new approach to control central deafferentiation pain: spinal intrathecal baclofen. Stereotactic Funct Neurosurg 65 1-4 (1995) 101-105
93. Loubser P.G., and Akman N.M. Effects of intrathecal baclofen on chronic spinal cord injury pain. J Pain Symptom Manage 12 4 (1996) 241-247
94. Zuniga R.E., Schlicht C.R., and Abram S.E. Intrathecal baclofen is analgesic in patients with chronic pain. Anesthesiology 92 3 (2000) 876-880
95. Lind G., Meyerson B.A., Winter J., et al. Intrathecal baclofen as adjuvant therapy to enhance the effect of spinal cord stimulation in neuropathic pain: a pilot study. Eur J Pain 8 4 (2004) 377-383
96. Denys P., Mane M., and Azouvi P. Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Arch Phys Med Rehabil 79 5 (1998) 494-496